Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E7AD
|
|||
| Drug Name |
Ibalizumab
|
|||
| Synonyms |
Hu5A8; TNX-355
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 42] | Approved | [1] | |
| Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Approved | [2] | ||
| Company |
TaiMed Biologics/Theratechnologies
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell surface glycoprotein CD4 (CD4) | Target Info | Modulator | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Antigen processing and presentation | ||||
| Hematopoietic cell lineage | ||||
| T cell receptor signaling pathway | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Pathway Interaction Database | TCR signaling in naï | |||
| IL12-mediated signaling events | ||||
| CXCR4-mediated signaling events | ||||
| C-MYB transcription factor network | ||||
| IL23-mediated signaling events | ||||
| Arf1 pathway | ||||
| Notch-mediated HES/HEY network | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | Binding and entry of HIV virion | |||
| Phosphorylation of CD3 and TCR zeta chains | ||||
| Translocation of ZAP-70 to Immunological synapse | ||||
| Generation of second messenger molecules | ||||
| PD-1 signaling | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Cytokines and Inflammatory Response | ||||
| Host Interactions of HIV factors | ||||
| Defensins | ||||
| HIV Life Cycle | ||||
| TCR signaling | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 761065. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.